Moving forward, biomarker-guided clinical trials integrating both tumor-intrinsic and microenvironmental cues-particularly IGF1R phosphorylation status and PTPN9 expression-will be instrumental in refining patient selection and optimizing therapeutic benefit. This evidence concerns the gene PTPN9 and neoplasm.